drugset / Trial / NCT05116826
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients
Non-randomizedParallel-groupOpen-labelBasic science
Summary
This study is being conducted to evaluate the major Nitazoxanide (NTZ) active metabolite in adult participants with hepatic impairment and healthy adults.
Timeline
- Start
- 2021-11-05
- Primary completion
- 2022-04-08
- Completion
- 2022-04-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nitazoxanide | Other / unclassified | 500 mg | Oral |